Registration number
breast cancer
SENTINEL LYMPH NODE, RECURRENCE, BREAST CANCER
NCT05160324 (In patients with cN0 T1–2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with mastectomy, the overall survival and recurrence-free survival rates of patients treated with sentinel lymph node biopsy only were not inferior to those treated with axillary lymph node dissection. To strengthen the conclusion of the trial, the enrolment of breast cancer patients with one to two positive sentinel lymph nodes treated with mastectomy was reopened. The long-term oncological outcomes in terms of survival and recurrence and the prognostic impact of the omission of axillary lymph node dissection in these patients remain to be seen.